Chinese Society of Sports Medicine, Email: 18980601388@163.com; Chinese Orthopaedic Association, Email: Ligp@263.net; Chinese Society of Physical Medicine and Rehabilitation, Email: cshiyi@163.com; Beijing Research Association for Chronic Diseases Control and Health Education, Email: hxkfhhc@126.com
Export PDF Favorites Scan Get Citation

Topical non-steroidal anti-inflammatory drugs (NSAIDs) are one of the commonly used drugs in the treatment of sports injury, but their standardized and rational use lacks evidence-based medical guidance. This guideline working group selected clinically important issues, fully collected the opinions of patients and clinical staff, and discussed them with the expert group. Based on the existing literature evidence, the "clinical practice guidelines for topical NSAIDs in the treatment of sports injury" was formulated following the methods and principles of international guidelines. In this guideline, 7 clinical concerns were finally selected, and a total of 22 recommendations were formed. Including the status, indications, contraindications, efficacy, combined application, use in special populations, adverse reactions, and countermeasures of topical NSAIDs in the treatment of sports injury. The purpose of this guideline is to provide evidence for orthopedics, sports medicine, rehabilitation medicine, sports science, and other practitioners in the treatment of sports injury, to promote the more standardized and rational use of topical NSAIDs.

Citation: Chinese Society of Sports Medicine, Chinese Orthopaedic Association, Chinese Society of Physical Medicine and Rehabilitation, China Sport Science Society of Sports Medicine, China Medicine Education Association, Beijing Research Association for Chronic Diseases Control and Health Education. Clinical practice guidelines for topical NSAIDs in the treatment of sports injury (2024 edition). Chinese Journal of Evidence-Based Medicine, 2024, 24(5): 497-509. doi: 10.7507/1672-2531.202402074 Copy

  • Next Article

    Policies for use of real-world data in drug reimbursement decision